Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma.
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback